Literature DB >> 28728747

Endothelial-to-Mesenchymal Transition in Bone Marrow and Spleen of Primary Myelofibrosis.

Benedetta Gaia Erba1, Cristian Gruppi2, Monica Corada1, Federica Pisati3, Vittorio Rosti4, Niccolo' Bartalucci5, Jean-Luc Villeval6, Alessandro Maria Vannucchi5, Giovanni Barosi4, Alessandra Balduini2, Elisabetta Dejana7.   

Abstract

Primary myelofibrosis is characterized by the development of fibrosis in the bone marrow that contributes to ineffective hematopoiesis. Bone marrow fibrosis is the result of a complex and not yet fully understood interaction among megakaryocytes, myeloid cells, fibroblasts, and endothelial cells. Here, we report that >30% of the endothelial cells in the small vessels of the bone marrow and spleen of patients with primary myelofibrosis have a mesenchymal phenotype, which is suggestive of the process known as endothelial-to-mesenchymal transition (EndMT). EndMT can be reproduced in vitro by incubation of cultured endothelial progenitor cells or spleen-derived endothelial cells with inflammatory cytokines. Megakaryocytes appear to be implicated in this process, because EndMT mainly occurs in the microvessels close to these cells, and because megakaryocyte-derived supernatant fluid can reproduce the EndMT switch in vitro. Furthermore, EndMT is an early event in a JAK2-V617F knock-in mouse model of primary myelofibrosis. Overall, these data show for the first time that microvascular endothelial cells in the bone marrow and spleen of patients with primary myelofibrosis show functional and morphologic changes that are associated to the mesenchymal phenotype.
Copyright © 2017 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28728747     DOI: 10.1016/j.ajpath.2017.04.006

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  8 in total

Review 1.  Endothelial to Mesenchymal Transition: Role in Physiology and in the Pathogenesis of Human Diseases.

Authors:  Sonsoles Piera-Velazquez; Sergio A Jimenez
Journal:  Physiol Rev       Date:  2019-04-01       Impact factor: 37.312

2.  Prevalence and Effect on Survival of Pulmonary Hypertension in Myelofibrosis.

Authors:  Matthew Austin; Peter J Quesenberry; Corey E Ventetuolo; Olin Liang; John L Reagan
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2019-05-13

3.  Integrated OMICs unveil the bone-marrow microenvironment in human leukemia.

Authors:  Diana Passaro; Manuel Garcia-Albornoz; Giovanni Diana; Probir Chakravarty; Linda Ariza-McNaughton; Antoniana Batsivari; Clara Borràs-Eroles; Ander Abarrategi; Alexander Waclawiczek; Luigi Ombrato; Ilaria Malanchi; John Gribben; Dominique Bonnet
Journal:  Cell Rep       Date:  2021-05-11       Impact factor: 9.423

Review 4.  Megakaryocyte Contribution to Bone Marrow Fibrosis: many Arrows in the Quiver.

Authors:  Alessandro Malara; Vittorio Abbonante; Maria Zingariello; Annarita Migliaccio; Alessandra Balduini
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-11-01       Impact factor: 2.576

Review 5.  Deciphering Tumor Niches: Lessons From Solid and Hematological Malignancies.

Authors:  Stéphane J C Mancini; Karl Balabanian; Isabelle Corre; Julie Gavard; Gwendal Lazennec; Marie-Caroline Le Bousse-Kerdilès; Fawzia Louache; Véronique Maguer-Satta; Nathalie M Mazure; Fatima Mechta-Grigoriou; Jean-François Peyron; Valérie Trichet; Olivier Herault
Journal:  Front Immunol       Date:  2021-11-10       Impact factor: 7.561

6.  TGF-β signaling in myeloproliferative neoplasms contributes to myelofibrosis without disrupting the hematopoietic niche.

Authors:  Juo-Chin Yao; Karolyn A Oetjen; Tianjiao Wang; Haoliang Xu; Grazia Abou-Ezzi; Joseph R Krambs; Salil Uttarwar; Eric J Duncavage; Daniel C Link
Journal:  J Clin Invest       Date:  2022-06-01       Impact factor: 19.456

7.  Elevated plasma EDA fibronectin in primary myelofibrosis is determined by high allele burden of JAK2V617F mutation and strongly predicts splenomegaly progression.

Authors:  Alessandro Malara; Cristian Gruppi; Margherita Massa; Maria Enrica Tira; Vittorio Rosti; Alessandra Balduini; Giovanni Barosi
Journal:  Front Oncol       Date:  2022-09-21       Impact factor: 5.738

Review 8.  Momelotinib: an emerging treatment for myelofibrosis patients with anemia.

Authors:  Helen T Chifotides; Prithviraj Bose; Srdan Verstovsek
Journal:  J Hematol Oncol       Date:  2022-01-19       Impact factor: 17.388

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.